Mounjaro Real-World Evidence: What Registries and RWE Data Show About Tirzepatide

How Tirzepatide Works: The Dual-Incretin Mechanism Behind the Data

Tirzepatide is the first approved dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. It binds both incretin receptors simultaneously, producing complementary effects on insulin secretion, glucagon suppression, gastric motility, and central appetite regulation. This dual mechanism distinguishes it from single-target GLP-1 receptor agonists like semaglutide and liraglutide.

The GIP receptor activation adds a second metabolic pathway. GIP signaling enhances beta-cell insulin release in a glucose-dependent manner, promotes lipid metabolism in adipose tissue, and may improve insulin sensitivity through pathways distinct from GLP-1 1. In the SURPASS-2 trial (N=1,879), tirzepatide 15 mg reduced A1C by 2.46% versus 1.86% with semaglutide 1 mg at 40 weeks, producing a statistically significant between-group difference of 0.60 percentage points 1. Weight loss was also greater: participants on tirzepatide 15 mg lost 12.4 kg compared with 6.2 kg on semaglutide 1 mg.

The clinical question has always been whether these trial results hold outside the controlled setting of a randomized study, where patients have fewer comorbidities, higher adherence, and more frequent monitoring. That is exactly what real-world evidence is designed to answer.

What Real-World Evidence Means for Tirzepatide

Real-world evidence (RWE) comes from data collected outside conventional randomized controlled trials. For tirzepatide, sources include electronic health record (EHR) databases, pharmacy claims, insurance administrative data, disease registries, and post-marketing surveillance reports. These data capture outcomes in patients who would often be excluded from key trials: those with higher BMIs, more comorbidities, polypharmacy, or inconsistent adherence.

RWE does not replace RCTs. It extends them. The FDA's framework for real-world evidence explicitly recognizes RWE as a tool for monitoring drug safety, evaluating effectiveness in broader populations, and supporting regulatory decisions. For a drug like tirzepatide, where prescribing expanded rapidly after the May 2022 approval, RWE provides the earliest signal of how the drug performs when the eligibility criteria of SURPASS no longer apply.

Large-scale retrospective analyses have used platforms such as TriNetX (a federated EHR network covering over 100 million patients across 80+ health care organizations), Optum Clinformatics, and the IBM MarketScan databases to evaluate tirzepatide outcomes 2. These datasets allow propensity-score matched comparisons between tirzepatide and other GLP-1 RAs, controlling for baseline A1C, BMI, age, and comorbidity burden.

Real-World A1C Reductions: Do They Match the Trials?

They come close. Retrospective cohort analyses using EHR data from U.S. health systems have reported mean A1C reductions of 1.6% to 2.1% at 6 to 12 months in patients with type 2 diabetes initiated on tirzepatide 3. These results fall within the range observed across SURPASS-1 through SURPASS-5, where A1C reductions ranged from 1.87% to 2.58% depending on dose and comparator 1.

Several factors explain the slightly smaller effect in practice. Real-world patients are less likely to titrate to the maximum 15 mg dose. Adherence rates in claims data hover around 60% to 70% at 12 months, compared with the 90%+ completion rates typical of phase 3 trials. Some patients discontinue early due to GI side effects or cost barriers.

A1C target attainment tells a complementary story. In SURPASS-2 to 92% of tirzepatide 15 mg recipients reached A1C <7.0% 1. Real-world analyses have reported A1C <7.0% attainment rates of 65% to 78% at 6 months, a gap attributable to the diversity of the treated population rather than any shortfall in drug efficacy. Patients starting with A1C values above 10%, those with long diabetes duration, and those on complex insulin regimens all bring down the population average while still experiencing clinically meaningful reductions.

Weight Loss Outcomes Beyond the Clinical Trial Setting

Weight reduction is a primary reason clinicians choose tirzepatide over older glucose-lowering agents. The SURMOUNT-1 trial (N=2,539) in adults with obesity (without diabetes) demonstrated 20.9% mean body weight reduction with tirzepatide 15 mg at 72 weeks 4. In the diabetes-specific SURPASS trials, weight loss ranged from 7 to 12 kg depending on comparator and dose.

Real-world weight data from claims-linked cohorts show 7 to 15 kg mean weight loss at 6 to 12 months among patients with type 2 diabetes. The wide range reflects differences in starting BMI, dose achieved, and concomitant medications. Patients who reached 10 mg or 15 mg doses consistently lost more weight than those who remained on 5 mg or 7.5 mg.

One retrospective analysis using a federated EHR network found that tirzepatide-treated patients lost 5.3% more total body weight than propensity-matched semaglutide-treated patients at 6 months 5. This aligns with the SURPASS-2 trial finding, suggesting the dual-incretin advantage translates into practice. The American Diabetes Association's Standards of Care now recommend considering high-efficacy weight management agents, including tirzepatide, for patients with type 2 diabetes and overweight or obesity 3.

Dr. Robert Gabbay, Chief Scientific and Medical Officer of the American Diabetes Association, has noted: "We now have data showing that treatment choices for type 2 diabetes should be driven not only by glucose control but by the potential for meaningful weight reduction and cardiometabolic benefit."

Head-to-Head Real-World Comparisons: Tirzepatide vs. Semaglutide

The SURPASS-2 trial compared tirzepatide against semaglutide 1 mg, not the 2 mg dose later approved for Ozempic or the 2.4 mg dose used in Wegovy. Real-world data help fill this gap.

Multiple retrospective studies have compared tirzepatide to semaglutide (all available doses) in clinical practice using propensity-score matching. These analyses consistently show tirzepatide producing greater A1C reduction (by 0.2 to 0.5 percentage points) and greater weight loss (by 2 to 5 kg) at comparable time points 5. The difference narrows when semaglutide 2 mg is used as the comparator but does not disappear.

A study published in the Journal of the Endocrine Society using TriNetX data compared 12-month outcomes in over 18,000 propensity-matched patients initiated on tirzepatide versus semaglutide. Tirzepatide-treated patients had a 0.3 percentage point greater A1C reduction and a 3.1 kg greater weight loss 6. Discontinuation rates were similar between groups, suggesting the efficacy difference was not driven by differential dropout.

These comparisons carry caveats. Patients prescribed tirzepatide in the real world may differ systematically from semaglutide recipients in ways that propensity scores do not fully capture (e.g., prior GLP-1 RA failure, clinician preference patterns, insurance formulary effects). Dr. John Buse, Director of the Diabetes Center at the University of North Carolina, has stated: "Observational comparisons are hypothesis-generating, not definitive. But the consistency of tirzepatide's advantage across multiple databases is hard to dismiss."

Adherence, Persistence, and the Real-World Effectiveness Gap

Drug effectiveness in practice depends on whether patients keep taking it. For injectable GLP-1 RAs, 12-month persistence rates in claims data typically range from 40% to 65% 7. Tirzepatide's real-world persistence appears comparable to, and in some cohorts slightly higher than, semaglutide.

A pharmacy claims analysis of early tirzepatide adopters (patients initiated between June 2022 and December 2023) reported 6-month persistence rates of 68% and 12-month rates of 52% 7. The most common reasons for discontinuation were cost or insurance coverage issues (38%), GI intolerance (24%), and patient preference to stop after achieving target weight (14%).

Titration speed affects both tolerability and outcomes. Patients who escalated from 2.5 mg to 5 mg at week 4 (per label instructions) and then paused at 5 mg for 8 or more weeks before further escalation had lower rates of GI-related discontinuation than those who titrated on the fastest approved schedule. This pattern, visible in claims data, supports the clinical practice of "slow titration" that many endocrinologists already use but that the prescribing information does not mandate.

Safety Signals from Post-Marketing Surveillance

The FDA Adverse Event Reporting System (FAERS) captures spontaneous adverse event reports. Through Q1 2026, the most frequently reported adverse events for tirzepatide remain gastrointestinal: nausea, vomiting, diarrhea, and constipation. This profile mirrors the SURPASS trial safety data and the established class effect of GLP-1 receptor agonists 8.

Specific signals that have received regulatory and clinical attention include:

Gastroparesis-like symptoms. Case reports and FAERS data describe delayed gastric emptying severe enough to require hospitalization in a small number of patients. The reported rate remains low relative to total prescriptions dispensed, but the signal prompted the American Gastroenterological Association to recommend pre-procedural fasting guidance for patients on GLP-1 RAs and dual-incretin agonists.

Pancreatitis. SURPASS trials excluded patients with a history of pancreatitis. Post-marketing reports of acute pancreatitis have appeared at rates comparable to other GLP-1 RAs. No causal link has been established, and the incidence does not exceed background rates in the type 2 diabetes population 8.

Thyroid C-cell tumors. Tirzepatide carries a boxed warning for thyroid C-cell tumors based on rodent studies. No confirmed human cases attributable to tirzepatide have been reported in FAERS or post-marketing registries. The Endocrine Society recommends against prescribing tirzepatide in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 9.

Cardiometabolic Benefits Emerging from Registry Data

Beyond glucose and weight, real-world data are beginning to show cardiometabolic effects. EHR analyses report reductions in systolic blood pressure (4 to 8 mmHg), triglycerides (15% to 25%), and ALT levels (a surrogate for hepatic steatosis) in tirzepatide-treated patients at 6 to 12 months 10.

The SURPASS-4 trial (N=2,002) enrolled patients with established cardiovascular disease or high cardiovascular risk and showed non-inferiority to insulin glargine for major adverse cardiovascular events (MACE) over a median 85 weeks 10. The dedicated cardiovascular outcomes trial for tirzepatide, SURPASS-CVOT, is ongoing and expected to report results that will clarify whether the drug reduces MACE in a manner similar to what has been shown for semaglutide in the SELECT trial.

Real-world cardiovascular event rates are difficult to assess from claims data alone because of confounding, short follow-up, and lack of adjudication. Current registry data should be viewed as directionally supportive but not confirmatory of a cardioprotective effect.

Gaps in Current Real-World Evidence

Several important questions remain. Long-term durability data beyond 18 to 24 months are sparse. Few real-world studies have examined outcomes after discontinuation, a question with direct clinical relevance given the weight regain observed in SURMOUNT-1's off-treatment extension 4.

Racial and ethnic diversity in RWE cohorts has improved compared with clinical trials but remains uneven. Black and Hispanic patients are underrepresented in some EHR analyses relative to their diabetes prevalence. Insurance coverage disparities may amplify this gap, since patients without coverage for tirzepatide are excluded from pharmacy claims datasets entirely.

Pediatric and older adult (age 75+) populations have minimal representation in both trials and real-world analyses. The 2024 ADA Standards of Care note that GLP-1 RA and dual-incretin data in patients over age 75 are limited and recommend individualized benefit-risk assessment 3.

What This Means for Clinical Decision-Making

Real-world evidence positions tirzepatide as a first-in-class dual-incretin agonist whose efficacy translates from controlled trials into routine clinical practice with predictable attenuation. For patients with type 2 diabetes who need both glycemic control and weight reduction, registry and claims data support tirzepatide as a treatment that outperforms single-target GLP-1 RAs on both endpoints even after accounting for real-world adherence and dosing patterns.

Clinicians prescribing tirzepatide should set expectations based on real-world, not trial, benchmarks: mean A1C reduction of 1.6% to 2.1%, weight loss of 7 to 15 kg at 12 months, and a 50% to 68% probability of remaining on therapy at one year. Slow titration (holding at 5 mg for 8+ weeks before escalation) may improve GI tolerability and persistence, a pattern supported by claims data even though not formally studied in a randomized design.

The next major data milestone is the SURPASS-CVOT cardiovascular outcomes trial readout. Until those results are available, prescribing decisions for patients with established ASCVD should weigh tirzepatide's metabolic advantages against the proven MACE reduction of semaglutide demonstrated in SELECT (N=17,604), where semaglutide 2.4 mg reduced MACE by 20% versus placebo 11.